Ordered accumulation of mutations in HIV protease confers resistance to ritonavir (original) (raw)

• Richman, D.D. Zidovudine resistance of human immunodeficiency virus. Rev. Infect. Dis. 12, S507–S512 (1990).
  Article Google Scholar
• Kempf, D. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92, 2484–2488 (1995).
  Article CAS Google Scholar
• Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528–1533 (1995).
  Article CAS Google Scholar
• Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534–1539 (1995).
  Article CAS Google Scholar
• Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).
  Article CAS Google Scholar
• Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995).
  Article CAS Google Scholar
• Cameron, B. et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB6a.
  Google Scholar
• Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571 (1995).
  Article CAS Google Scholar
• Pachl, C. et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 8, 446–454 (1995).
  Article CAS Google Scholar
• Myers, G., Wain-Hobson, S., Korber, B., Smith, R.F. & Pavlakis, G.N. Human Retroviruses and AIDS (Los Alamos National Laboratory, Los Alamos, New Mexico, 1993).
  Google Scholar
• Markowitz, M. et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701 (1995).
  CAS PubMed PubMed Central Google Scholar
• Jacobsen, H. et al. In-vivo resistance to HIV proteinase inhibitor saquinavir—an update. AIDS Res. Hum. Retrovir. 11, S169–S169 (1995).
  Google Scholar
• Pauwels, R. et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309–321 (1988).
  Article CAS Google Scholar
• Partaledis, J.A. et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethy-lamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69, 5228–5235 (1995).
  CAS PubMed PubMed Central Google Scholar
• Patick, A.K. et al. Antiviral and resistance studies of AG 1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40, 292–297 (1996).
  Article CAS Google Scholar
• Schapiro, J.M. et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. (in the press).
• Heath-Chiozzi, M. et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB6b.
  Google Scholar
• Gulick, R. et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan. 28–Feb. 1, 1996, Abstract LB7.
  Google Scholar
• Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582–1586 (1996).
  Article CAS Google Scholar
• Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483–489 (1995).
  Article CAS Google Scholar
• Ho, D.D. et al. Characterization of HIV-1 variants with increased resistance to a C 2 symmetric protease inhibitor. J. Virol. 68, 2016–2020 (1994).
  CAS PubMed PubMed Central Google Scholar
• Gulnik, S.V. et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282–9287 (1995).
  Article CAS Google Scholar
• Jacobsen, H. et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206, 527–534 (1995).
  Article CAS Google Scholar
• Kitchen, V.S. et al. Safety and activity of saquinavir in HIV infection. Lancet 345, 952–955 (1995).
  Article CAS Google Scholar
• Japour, A.J., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37, 1095–1101 (1993).
  Article CAS Google Scholar
• Maschera, B., Furfine, E. & Blair, E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69 5431–5436 (1995).
  CAS PubMed PubMed Central Google Scholar